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associated CHD risk factors (RF) in asymptomatic siblings of persons with
documented premature CHD (<60 years of age). Using the JNCVguidelines,
fJ09siblings (52% male, 17%African American) were classified into treatment
cstegorfes. The prevalence of HTN (2140/90 mmHg, defined by an average
of three resting measures using AHA guidelines) was 38%: half of these
hypertensive siblings met criteria for nonpharmacologic intervention, and the
other half for drug treatment. Among those requiring treatment according
to JNC V, only 56Y0 were aware that they had HTN. This is extremely
important, given the high prevalence of other CHD RF among those eligible
for treatment: 73% were hypercholesterolemic (LDL ? 130 mg/dl); 59% were
obese, aooording to NCHS atandards; 27% were current smokers; and 85%
were consuming more than 30% of calories from fat. Of those eligible for
drug treatment, only 41% were on antihyperfensives, the majority of which
were diuretics. These findings indicate a markedly high prevalence of HTN
wmbined with iow awareness and treatment levels, which particularly in
the presence of mdtlphRF, demonstrate the need for moreaggressive
screening and treatment in this high-risk population.
El952154 Hyperinsullnemia,OverweightandHighBloodPressureIn YoungAdults-The RiodeJaneiro
Study
R. Pozzen, S.L.D. Silva, A.A. BrandFro,A.P. Brandao. L)eptot
Cardiology-StateUniversityof RiodeJaneiro,13rasil
We analyzed the relationship of hyperinsulinemia and overweight in young
adufts (17-23 Yrs) with different percentiles of blood pressure. We evaluata
3906 children and adolescents (10-15 yrs) In their schools in ordar to deter-
mine blood pressure (BP) cuwes. 64 individuals out of these population were
accompanied throughout 8 years in four consecutive screening and stratified
in 3 groups according to the tracking of BP: Group 1 (n = 23, 12 malas) with
BP ? 95th percentile in at least 3 out of 4 evaluations; Group 2 (n = 28, 13
males) with BPs 50’0 percentile Inat least 3 out of 4 screenings and Group 3
(n= 13,3 males) without stable BP percentile. All 64 subjects were submitted
to an oral glucose tolerance test with 75 g of dextrosol, after 12 hours fasting.
Blood samples were collected at O, 30, 60, 90 and 120 minutes for insulin
and glucose measurements. Ovenveight was defined as a body mass index
(BMI) z 25 k@m2:BI ? 30 &lU/ml was considered abnormal, peak value
of insulin (PVI) and gkrmse (PVG) were defined as the highest value after
stimulus and WHO’s criteriou$ were used to identify individuals with glucose
Intolerance (Gl). BMI, systolic (SBP) and diastolic blood pressure (DBP)
were also used for comparison and correlation among the groups. The main
results were: 1) There were no age or sex differences among the groups (p >
0.05); 2) Group 1 had greaterBMl(66.8+2.8x 80.8& 1.5 x 59.3 +2.4 p <
0.02), SBP (128.3+ 2.3 x 109.9 + 1.6 x 115.5+ 1.7p < 0.0001) and DBP
(78.6 & 1.5 x 64.9 + 1.6 x 71.8 + 2.4p < 0.0001) than the other groups;
3) Group 1 had graater BI (17.1 + 2.8 x 8.8 + 0.9 x 10.3 + 1.6p < 0.02),
BG (90.9 + 2.3 X 81.6& 1.6 X 81.6 + 2.2p < 0.0005), PVI (153.4& 76.1
x 96.9 + 33.3 x 123.2 + 54.9 p < 0.005) and PVG (141.3 + 21.0 x 121.1
+ 23.2 x 120.0 + 28.2 p < 0.005) than the other groups; 4) Group 1 had
more prevalence of overweight (6.7% x 32.0% O%p < 0.05) and abnormal
values of BI (3.6% x 21.7% x OYOp < 0.05) than the other groups; 5) GI wee
more prevalent in group 1 than in group 2 (13.I’Yo x O%p < 0.05); 6) The
multivariated analysis showed that SBP was significantly correlated with all
insuiin variables, even when BMI was statistically controlled. We concluded
that the association of high blood pressure, high insulin and glucose levels
and body size can be detected early, but the meaning of these findings would
be better explained on longitudinal studies.
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m923135 Cost-EffectivenessAnalysisofan EarlyLisinopril
usein PatientsWithAcuteMyocardialInfarction:
ResultsFromGISSI-3Trial
M.G. Franzosi, A.P. Maggioni, E. Santoro, G. Tognoni for the GISSI-3
Investigators. ktituto MarioNegri,Italy
As cost containment of the health care system has become a priority, clinical
trialsare now more likely to measure cost-effectiveness outcome as well as
medical outcome. GISSI-3 study tested an early (within 24 hours) treatment
of ACE-inhibitor (Iisinopril) for42 days in 19,394 relatively unselected patients
with acute myocardlal infarction. A statistically significant reduction of 6 week
mortality was achieved in Iisinopril allocated patients when compared to
nolisinopril allocated patients [7.5 (SD 3.8) lives saved per 1,000 treated
patients].
We performed a cost-effectiveness analysis in the total population admit-
tedto GISS1-3study,usingdetaontheuseof medical resourcas prospectively
collected during hospitalization. Charges were converted to costs. Effective-
nesswasmeasured in terms of number of additional survivors among patients
assigned to Iisinopril group. Cost-effectiveness ratios were expressed as cost
per premature death avoided.
On the basis of the 6-week survival analysis of GISS,I-3study, the com-
parative cost-effectiveness ratio iorthe use of Iisinopril was 2,300 US dollars
per premature death avoided.
A sensitivity analysis was conducted to examine the effects of varying the
estimated absolute reduction in monality of 7.5 lives saved per 1000 treated
patients) throughout itsconfidence interval (95% Cl: 0.4 to 14,6 lives saved
per 1,000 treated patients). The cost-effectiveness ratios consequently could
vary from 43,300 to 1,2C0US dollars per premature death avoided.
The cost-effectiveness of Iisinopril treatment compares very favorably
with that of other interventions for acute myocardlal infarction,
1923-136] EValuatlonofChestPaininthe EmergencyRoom:
IeThereGenderBias?A PopulationBaeadStudy
inOfmstedCounty,Minnesota
V.L, Rogar, S.E. Gabriel, G.S, Reeder, P.A.Smars, S.L. Kopecky,
K.A. Traverse, A.R, Zinsmeister, M.E. Farkouh. MayoC/inic,ROohestec
MN,USA
The existence of gender bias in the delivery of cardiac care remains con-
troversial, but if it exists, it may occur at the earliest point in the diagnostic
sequence. We reporf herein the results of the first population-based study
examining sex differences in evaluation and outcome after the first emer-
gency room (ER) visit for chest pain (CP). Between 1985 and 1992, 691
Olmsted County residents (433 men, 258 women), were seen in the ER for
CP.Except forage (women older), men and women were similar in baseline
characteristics, type of CP or ECG findings. Adjustment for baseline charac-
teristics and risk sfatus (AHCPR unstable angina guidelines) was pertormed
with multivariate analysis for the 2 endpoints: utilization of procedures and
outcome. The percentages of men and women having procedures within 90
days after ER visit were:
Men Women pvalue*
?3 procedures 17,20/. 11.6”A <0.01
Any Cardiac Diagnostic 81% 65”A <0.005
AnyCardiacTherapeutic 23,6% 14.s% <0.005
Any GI Diagnostic 12% 15.8°A NS
*p valuesareadjustedforfactorsrelatedto proceduraluse.
After a median follow-up of 4.9 years, 200 cardiovascular events (my-
ocardial infarcti, heart failure, cardiac arrest, cardiac death, and stroke)
were recorded. After adjustment, female sex was not associated with time to
first event.
These population-based data indicate that, affera first ERvisit for CP: (1)
utilization of procedures is lower in women (2) despite this, women do not
appear at increased risk for cardiovascular events.
m923137 MarkedReductionsinOutpatient,Inpatient,andTotafMedicalCostswithComprehensive
Work-SitePrimaryPreventionPrograme
R.V.Milani, C.J. Lavie. OchsnerMedica/Institutions,NewOr/eana,LA,USA
Previous studies have demonstrated that a small minority of employees uti-
Iizethe majorityof corporate health costs, which can be reduced by improving
overall risk status. In a pilot work-site project study of 164 participants and
161 nonparticipants, we aee$ssed the effects of a comprehensive risk as-
sessment and modification program (RAMP) on overall outpatient, inpatient,
and total (inpatient, outpatient, emergency room, and pharmacy) annualized
medical costs before and after a 6 month intervention program. At baseline,
42 (26%) were classified as “high-risk” by anthropometric measurements,
lipids, smoking and blood pressure status, as well as overall health habits
and behavioral data. Following RAMP, high-risk patients markedly improved
their overall health risk score by 40% (p c 0,01), 57?&of whom achieved
low-risk status, Furthermore, low-risk participants improved thair mean total
health score by 10% (p < 0.001). Following RAMP,outpatient medical costs
fell by 35% (p c 0.01) in participants compared to a 16% increase (p <
0.05) in nonparticipants (p <0.01 between groups). In addition, inpatient
costs fell by 73% (p < 0.001) in participants compared with 60% (p < 0.001)
in nonparticipants, resulting in a total reduction in medical costs of 48%
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in participants compared with 16Y0in nonpatiicipants (p <0.001 between
groups). These results translate into a $660 SSVin95Per emPloYeePerYear
in medical claims costs for RAMP participants. Conclusion: Theae coat date
support the potential for work-site primary prevention programs to signifi-
cantly improve employee health which in turn reduce annual medical claims.
These programs should be considered by industry and managed haalth care
organizations in cost-effective health maintenance.
B923138 Medical Intervention in Unatsble Angina: DoesInternational Clinical Practice Match
Evidence-Baaed Guideline?
K.P.Alexander, E.D. Peterson, K.W. Mahaffey,A.C. Casas, C.B. Granger,
F.Van de Werf, P.W.Armstrong, D.B. Mark, E.J. Topol, R.M. Califf for the
GUSTO Ilb Investigators. Duke University Durham, NC, USA
Guidelines have bean asfablished for the use crfmedications in patients with
unstable angina. To determine how international clinical practice matches
these recommendations, we evaluated discharge medicstiona from 7,743
unstable angina patients enrolled in GUSTO Ilb. Using established criteria
for usa and avoidance of each medication, we examined the use of threa
medications (aspirin [ASA], bate blockers [BB], ACE inhibitors [ACEi]), and
the avoidance of a fourth (calcium blockers [CaB]). We compared medication
use at discharge in ‘All’ patients, and in ‘Ideal’ patients defined as those
eligible for each treatment without identifiable contraindications.
Medicationat US(2183) Canada(892) Europe(4468)
Discharge All Ideal All Ideal All Ideal
ASA (%) 82.2 83.9 85.2 86.4 82.5 86.1
BB(%) 52.6 58.8 65.8* 69.8* 54,0 57.3
ACEI (%) 23.4 54.6 21.1 49.2 22.3 49.1
CaB (%) 38.0 25,1+ 34.2* t8.7t 44.3 31,6t
*p <0.001 Canada vs. othara for All and Ideal use, tO/. use of CaS in PISin whom uae
was contraindicated
Corrc/usiorr.’Although Canada diaplayad a practice pattern more consis-
tent with published guidelines, all geographic regions demonstrated under-
utilization of appropriate drug therapy in unstabla angina.
m923139 10-year Trends in CHF Hospitalization Rstes,Duration and Outcome
B.M. Massie, N.B. Shah. University of California and VAMC,San Francisco,
CA, USA
CHF is a major source of morbidity and health cere costs, and therefore has
bean a target for both pharmacologic and non-pharmamlogic interventions.
To determina whether changes in hospital discharges (DC), length of stay,
and outcomes have occurred, wa examined data for CHF hospitalizations
(ICD-9 428.0) from the National Hospital Discharge Survey for 1993, the last
available year, and the preceding decade. As shown in the table, there has
been a dramatic rise DC number and rate, although this has been partially
counterbalanced by a decreasing length of stay (LOS). Although the great
majority of hospitalized patients were elderly (78% ?65; 53% >75) and
hoapital mortality rates are much higher in the elderly (7.2Y0265 vs 2.8Y0
< 66), they have deciinad from 9.7Y0to 6.IYo over 10 years. DC rates per
10,000 were higher in women then men (36.2vs32.0) and African Americans
than whites (S3.3 vs 28.6). Major regional variations were notad, with DC
rates (per 10,000) ranging from 39 in the South, 38.5 in the Northeast, 37.5
in the Midwe$t, to 18 in the West, with corresponding average LOS of 7.0,
9.5,7.1, and 6.2 days, respectively.These data indicate that CHF remains a
major health and socio-aconomic problem, but aiso suggest that changes in
management ara impacting on LOS and short-term outcome.
El923140 Over and Underuse of RevsscularizstionProcedures in Italy
F. Valagussa 1, A. Liberati 2, A.P. Maggioni 2, L. Valagussa 1, G. Filardo2,
G. Mura2. i S. Garardo /-fospita/,Monza, Italy, 2Mario Nagrihsfituta,
Mi/ano, /ta/y
Most studies on appropriateness of cardiac revascularization procedures
have been aimed at detecting “overuse” (ie when patients get a procedure
without a clear indication) whila still Iittla attention has been paid to “undar-
use” (when patients who could benefit from a procedure do not get it). A
multidisciplinary experl panel convened by the Italian Association of Hos-
pital Cardiologists (ANMCO) ratad the appropriateness of 898 “theoretical
indications” for Coronary Artery by Pass Grafting (CABG) and Percutaneous
Transluminal Angioplasfy (PTCA) using the RAND Corporation methodology.
For CABG 37% indications were considered “appropriate”, 42% “equivocal”
and 21 “inappropriate”; for PTCA corresponding figures were 23%, S5% and
22%. These criteria were compared to theacfual indications given after coro-
nary angiography to a cohorl of 1811consecutive patients seen at 16 centers
in Northern Italy in 1995 to assess the appropriateneas of clinical indications.
Fiffyeight percent patientato whom amedicsl therapy wasprescrfbsd should-
according tothepanel criteria-have received an indication for CABGor PTCA
(see below). Most of the indications for CABG were appropriate while almost
haif of the indications for PTCAfelled into the “equivocal” category, Thepapar
also presents figures on the eventual utilization of CABGIPTCA at 9 months
follow-up after angiography.
Compariaonofindicationsaftercoronaryangiographyandthecrltariaagreedbythaexpetl
panel(Pts = 1811)
Indication after Expert panel criteria
angiography Appropriate nQ(%) Equivecal nQ(OA) Inappropriata nQ(%) Totsl
Medical theraDv 57 114) 117 (28) 239 (58) 413
CABG “ 565~80j 111(14j 39 (6j 7t6
PTCA 262(39) 300(44) 121(17) 633
Total 884(49) 528 (29) 399 (22) 1811
1923-141 I Angioplasty(PTCA): Outcomes inthe Veterana
Administration (VA) snd the Privste Sector
(Washington State)
J.L. Ritchie, C. Maynard, M. Chapko, N. Every, D. Martin. Seattle Veterans
Administration /-/ospita/arrd U. of Washington, Seattle, WA, USA
Using administrative hospital discharge data, we compared 10 day mortality
between men in the VA nationally and men in the State of WA for 1993-94.
In the VA system, only 50 larger hospitals with cardiac surgety progrema
periorm PTCA. Institutional PTCA volumea were, however, generally low in
the VA (range 16-21B/yr,9/50 or 18%did ?150/yr). In WA State 1W23(560A)
canters did ?150/yr, (range 5-920, mean 266/yr). For patiants with same
admission AMI, 10 day mortality was 3.9~o in the VA (67/1727) vs. 3.5% in
WA State (97/2773), p = NS. For non AMI patients, mortality was 0.5% in the
VA (3W6599)vs 0.4% in WA State (18/4588), p = NS.
Co-morbidities of diabetes, hypertension, renal, liver and pulmonary dis-
ease, and CHF were more common in VA patienta. Co-morbidities such es
CHF (which could have been complications of the procedure), were con-
sidered only if preaent on a prior admission. With logistic regression, risk
adjusted mortality was not different in the two systems. For AMI patients, VA
axpactad mortality was 4.0% (obsarvad = 3.9~o), and WA State expected
mortality was 3.4% (obsewad 3.5%), p = NS. For non AMI patients, VA
expected mortality was 0.5?4 (obsarvsd = 0.5%), and WA State expected
mortality was 0.5% (obsewed 0.5%), p = NS.
We conclude that in a tiered national VA system, risk adjuated motility
was no differant than that of a state wide private systam.
Year Heap DCS DC Rate Hosp Daya LOS Mortality
19s3 463,000 2W1O,OOO 4,484,000 9.7d 9.7”h
19s8 624;000 2S/10,000 5,560,000 8.8 d 8.5”k
18s3 876,000 Wlo,ooo 6,567,000 7.5d 6.1”/0
